Executives at Genmab are confident that the firm has an edge over Roche in the new class of CD20xCD3 bispecific antibody lymphoma therapies, although it could still be beaten to the US market by their rivals.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?